Company Description
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications.
The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery.
The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery.
In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature.
The company sells its products directly to hospitals and other healthcare facilities through independent sales agents.
The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023.
Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
| Country | United States |
| Founded | 2015 |
| IPO Date | Oct 8, 2020 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 26 |
| CEO | C. Mills |
Contact Details
Address: 20 Firstfield Road Gaithersburg, Maryland 20878 United States | |
| Phone | 240 247 1170 |
| Website | elutia.com |
Stock Details
| Ticker Symbol | ELUT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 1708527 |
| ISIN Number | US05479K1060 |
| Employer ID | 47-4790334 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. C. Randal Mills Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Matthew B. Ferguson | Chief Financial Officer |
| Dr. Michelle LeRoux Williams Ph.D. | Chief Scientific Officer |
| Dr. Sonali Fonseca Ph.D. | Vice President and Head of Emerging Businesses |
| Dwayne Montgomery | Head of Cardiovascular |
| Pete J. Ligotti | Chief Commercial Officer |
| Jeffry D. Hamet | Senior Vice President of Finance, Treasurer and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 13, 2026 | 10-K | Annual Report |
| Mar 11, 2026 | 8-K | Current Report |
| Mar 9, 2026 | 8-K | Current Report |
| Mar 4, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | SCHEDULE 13G | Filing |
| Jan 28, 2026 | SCHEDULE 13G/A | Filing |
| Jan 12, 2026 | 8-K | Current Report |